Novo Nordisk stock faces bearish technicals, but analysts forecast nearly 46% upside. Novo inks $285 million Ascendis ...
Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities ...
Novo Nordisk (NVO) has released an update. Novo Nordisk has successfully concluded a share repurchase program initiated on August 7, 2024, ...
Novo Nordisk ( NVO, Financials) entered an exclusive agreement with Ascendis Pharma ( ASND, Financials) to license Ascendis's TransCon technology platform for developing novel treatments targeting ...
Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ascendis Pharma (ASND – Research ...
Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its ...
Novo Nordisk is scheduled to report results for the third quarter on Wednesday. Here is what you need to know: NET PROFIT FORECAST: Net profit in the quarter is expected to rise 19% to 26.79 billion ...
Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its ...
BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of ...